Blog | MedMira News

Kopie der klinischen Studien mit dem Multiplo® Complete Syphilis (TP/nTP)-Antikörpertest beginnen - ein potenzieller Wendepunkt zur Bewältigung der Syphilis-Gesundheitskrise in Kanada

MedMira

13. Aug.
5 Min.

Kopie der klinischen Studien mit dem Multiplo® Complete Syphilis (TP/nTP)-Antikörpertest beginnen - ein potenzieller Wendepunkt zur Bewältigung der Syphilis-Gesundheitskrise in Kanada

Halifax, Nova Scotia, 13. August 2024 – Heute gibt MedMira Inc. (MedMira) (TSXV: MIR) bekannt, dass es umfassende klinische Studien für...

MedMira

30. Apr.
2 Min.

MedMira Announces the Hire of Vice President of Business Development

Halifax, Nova Scotia, 30 April, 2024 – Today, MedMira Inc. (MedMira) (TSXV: MIR) is pleased to announce the expansion of their...

MedMira

19. Apr.
1 Min.

Innovation made easy

With MedMira's patented RVF Technology, there are a myriad of possibilities: As an example, our latest custom made product for one of our...

MedMira

13. März
4 Min.

MedMira Receives Canadian Patent for its Unique Quantitative Diagnostic System

Halifax, Nova Scotia, March 13, 2024 – Today, MedMira Inc. (MedMira) (TSXV: MIR) announces the receipt of a Canadian patent...

MedMira

1. Feb.
3 Min.

Corporate Update on Clinical Evaluation of MedMira’s Products

Halifax, Nova Scotia,1 February, 2024 – Today, MedMira Inc. (MedMira) (TSXV: MIR) is pleased to provide an update on the ongoing review...

MedMira

14. Dez. 2023
3 Min.

U.S. FDA Approves MedMira’s Advanced Reveal® G4 Rapid HIV-1/2 Antibody Test

Halifax, Nova Scotia, 13 December, 2023 – Today, MedMira Inc. (MedMira) (TSXV: MIR) MedMira Inc. proudly announces today the successful...

2 3 4 5